Bachem Holding AG
SIX:BANB

Watchlist Manager
Bachem Holding AG Logo
Bachem Holding AG
SIX:BANB
Watchlist
Price: 67.8 CHF 0.59%
Market Cap: 5.1B CHF
Have any thoughts about
Bachem Holding AG?
Write Note

Bachem Holding AG
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bachem Holding AG
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Bachem Holding AG
SIX:BANB
Other Current Liabilities
CHf127.5m
CAGR 3-Years
56%
CAGR 5-Years
64%
CAGR 10-Years
34%
Siegfried Holding AG
SIX:SFZN
Other Current Liabilities
CHf164.2m
CAGR 3-Years
11%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Lonza Group AG
SIX:LONN
Other Current Liabilities
CHf2.1B
CAGR 3-Years
-2%
CAGR 5-Years
5%
CAGR 10-Years
8%
Tecan Group AG
SIX:TECN
Other Current Liabilities
CHf177.7m
CAGR 3-Years
8%
CAGR 5-Years
13%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Other Current Liabilities
€53.7m
CAGR 3-Years
4%
CAGR 5-Years
34%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Other Current Liabilities
CHf146m
CAGR 3-Years
3%
CAGR 5-Years
407%
CAGR 10-Years
N/A
No Stocks Found

Bachem Holding AG
Glance View

Market Cap
5.1B CHF
Industry
Life Sciences Tools & Services

Bachem Holding AG engages in the provision of peptides and oligonucleotides. The company is headquartered in Bubendorf, Basel-Landschaft and currently employs 1,639 full-time employees. The company went IPO on 2001-06-29. The firm focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The firm markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.

BANB Intrinsic Value
91.5 CHF
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Bachem Holding AG's Other Current Liabilities?
Other Current Liabilities
127.5m CHF

Based on the financial report for Jun 30, 2024, Bachem Holding AG's Other Current Liabilities amounts to 127.5m CHF.

What is Bachem Holding AG's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
34%

Over the last year, the Other Current Liabilities growth was 2%. The average annual Other Current Liabilities growth rates for Bachem Holding AG have been 56% over the past three years , 64% over the past five years , and 34% over the past ten years .

Back to Top